- Home
- PHAR vs IMNM Comparison
PHAR vs IMNM Comparison
Compare PHAR & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- IMNM
- Stock Information
- Founded
- PHAR 1988
- IMNM 2006
- Country
- PHAR Netherlands
- IMNM United States
- Employees
- PHAR N/A
- IMNM N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- PHAR Health Care
- IMNM Health Care
- Exchange
- PHAR Nasdaq
- IMNM Nasdaq
- Market Cap
- PHAR 1.0B
- IMNM 945.8M
- IPO Year
- PHAR N/A
- IMNM 2020
- Fundamental
- Price
- PHAR $14.60
- IMNM $10.04
- Analyst Decision
- PHAR Strong Buy
- IMNM Strong Buy
- Analyst Count
- PHAR 3
- IMNM 8
- Target Price
- PHAR $30.00
- IMNM $24.75
- AVG Volume (30 Days)
- PHAR 11.5K
- IMNM 756.6K
- Earning Date
- PHAR 10-23-2025
- IMNM 08-06-2025
- Dividend Yield
- PHAR N/A
- IMNM N/A
- EPS Growth
- PHAR N/A
- IMNM N/A
- EPS
- PHAR N/A
- IMNM N/A
- Revenue
- PHAR $339,836,000.00
- IMNM $12,589,000.00
- Revenue This Year
- PHAR $16.63
- IMNM N/A
- Revenue Next Year
- PHAR $6.77
- IMNM $154.73
- P/E Ratio
- PHAR N/A
- IMNM N/A
- Revenue Growth
- PHAR 22.44
- IMNM 16.74
- 52 Week Low
- PHAR $7.06
- IMNM $5.15
- 52 Week High
- PHAR $17.08
- IMNM $16.73
- Technical
- Relative Strength Index (RSI)
- PHAR 57.37
- IMNM 51.10
- Support Level
- PHAR $13.51
- IMNM $8.67
- Resistance Level
- PHAR $15.61
- IMNM $10.65
- Average True Range (ATR)
- PHAR 0.87
- IMNM 0.65
- MACD
- PHAR -0.06
- IMNM -0.03
- Stochastic Oscillator
- PHAR 59.37
- IMNM 64.19
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.